| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cell Growth & Differentiation |
Suppresses Migration of Mouse Melanoma Cells1
Department of Chemistry and Biochemistry [E. S-N., S. A. R.] and Graduate Center [E. S-N.], Queens College of the City University of New York, Flushing, New York 11367, and Center for Experimental Therapeutics and Department of Pharmacology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania [N. F., M. G. K.]
Mouse melanoma B16 F1 cells cultured in RPMI 1640 supplemented with the melanin precursors tyrosine and phenylalanine display increased melanin levels and elevated migration while down-regulating protein kinase C (PKC)
to low levels. Although control experiments rule out a direct role by melanin, PKC
down-regulation is shown to be a critical determinant of cell migration. Transfection of high-motility cells with either wild-type PKC
or its regulatory domain suppresses migration. Known to bind to the regulatory domain of PKC
, the proapoptotic protein prostate apoptosis response-4 (Par-4) coimmunoprecipitates with PKC
as a 47-kDa protein. Transfection of Par-4 (or its leucine zipper element) further suppresses migration of low-motility cells (which express high levels of PKC
), whereas high-motility cells (which express low levels of PKC
) are unaffected by Par-4 overexpression. It is proposed that in nonmetastatic cells, the PKC
Par-4 complex provides a brake on migration that is released by melanin precursors that initiate PKC
down-regulation. Elevation of PKC
in melanoma cells, or preventing its down-regulation through the dietary restriction of tyrosine and phenylalanine, may therefore control metastatic behavior.
This article has been cited by other articles:
![]() |
P. RANGANATHAN and V. M. RANGNEKAR Regulation of Cancer Cell Survival by Par-4 Ann. N.Y. Acad. Sci., November 1, 2005; 1059(1): 76 - 85. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cell Growth & Differentiation |